Experimental Alzheimer’s Drug Lowers Tau Levels but Yields Mixed Results
Researchers testing a novel monoclonal antibody for Alzheimer’s disease have observed a significant reduction in brain tau protein levels, a hallmark of neurodegeneration. While the drug slowed cognitive decline, the ... Read More